Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.60 |
| ▸ | ILK | Q13418 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 9/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30365100 | 0.89 | AHR (0.60) | AHRILKAPPMAPTTP53 | |
| SCHEMBL3050082 | 0.89 | AHR (0.60) | AHRILKAPPMAPTTP53 | |
| SCHEMBL30966554 | 0.89 | AHR (0.60) | AHRILKAPPMAPTTP53 | |
| SCHEMBL11188660 | 0.83 | AHR (0.56) | AHRILKAPPMAPTTP53 | |
| SCHEMBL19985005 | 0.83 | AHR (0.59) | AHRILKAPPMAPTTP53 | |
| SCHEMBL30966559 | 0.83 | AHR (0.59) | AHRILKAPPMAPTTP53 | |
| SCHEMBL30966572 | 0.83 | AHR (0.59) | AHRILKAPPMAPTTP53 | |
| SCHEMBL2240330 | 0.81 | APP (0.65) | APPMAPTTP53SMN1; SMN2KDM4E | |
| SCHEMBL31471859 | 0.81 | APP (0.65) | APPMAPTTP53SMN1; SMN2KDM4E | |
| SCHEMBL5691159 | 0.81 | APP (0.77) | AHRILKAPPMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005744-B2 | Compounds for the treatment or prevention of breast cancer | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2018-06-26 | — | — | US | disclosed |
| US-20180134673-A1 | COMPOUNDS FOR THE TREATMENT OR PREVENTION OF BREAST CANCER | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005744-B2 | Compounds for the treatment or prevention of breast cancer | BRCA1, CYP19A1, PGR | AHR 442/4885ILK 3718/4885APP 4193/4885 |
| US-20180134673-A1 | COMPOUNDS FOR THE TREATMENT OR PREVENTION OF BREAST CANCER | BRCA1, CYP19A1, PGR | AHR 442/4885ILK 3718/4885APP 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.